{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:29:35Z","timestamp":1762651775824,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2017-00847"],"award-info":[{"award-number":["2017-00847"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen Pharma SAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["2019-0030"],"award-info":[{"award-number":["2019-0030"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.esmorw.2025.100122","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T16:34:18Z","timestamp":1741106058000},"page":"100122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Guidelines and variations in patterns of GnRH analogue use in castration-resistant prostate cancer across six countries"],"prefix":"10.1016","volume":"7","author":[{"given":"G.","family":"George","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Enting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Garmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Stattin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.F.","family":"Lissbrant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Monroy-Iglesias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.-M.","family":"Scailteux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Balusson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Van Praet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Lumen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Marvaso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Corrao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.A.","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Chehade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Shamseddine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Charafeddine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Van Hemelrijck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.esmorw.2025.100122_bib1","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmorw.2025.100122_bib2","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","article-title":"Hormonal impact of the 17alpha-hydroxylase\/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer","volume":"90","author":"O\u2019Donnell","year":"2004","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.esmorw.2025.100122_bib3","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00345-014-1406-2","article-title":"Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?","volume":"33","author":"Merseburger","year":"2015","journal-title":"World J Urol"},{"issue":"11","key":"10.1016\/j.esmorw.2025.100122_bib4","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.esmorw.2025.100122_bib5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmorw.2025.100122_bib6","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41391-022-00533-6","article-title":"LHRH sparing therapy in patients with chemotherapy-na\u00efve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial","volume":"25","author":"Ohlmann","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.esmorw.2025.100122_bib7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/21681805.2021.2019304","article-title":"Androgen deprivation therapy, comorbidity, cancer stage and mortality from COVID-19 in men with prostate cancer","volume":"56","author":"Gedeborg","year":"2022","journal-title":"Scand J Urol"},{"issue":"6","key":"10.1016\/j.esmorw.2025.100122_bib8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.therap.2023.01.009","article-title":"Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): how to translate guidelines into practice","volume":"78","author":"de Germay","year":"2023","journal-title":"Therapie"},{"issue":"26","key":"10.1016\/j.esmorw.2025.100122_bib9","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.esmorw.2025.100122_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur Urol"},{"issue":"suppl 16","key":"10.1016\/j.esmorw.2025.100122_bib11","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1200\/JCO.2024.42.16_suppl.5086","article-title":"Abiraterone with discontinuation of gonadotropin-releasing hormone (GnRH) analogues in patients (pts) with metastatic prostate cancer (PC): a single arm, phase II study","volume":"42","author":"Makrakis","year":"2024","journal-title":"J\u00a0Clin Oncol"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820125000116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820125000116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:25:12Z","timestamp":1762651512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820125000116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":11,"alternative-id":["S2949820125000116"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100122","relation":{},"ISSN":["2949-8201"],"issn-type":[{"type":"print","value":"2949-8201"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guidelines and variations in patterns of GnRH analogue use in castration-resistant prostate cancer across six countries","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2025.100122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100122"}}